TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06172699

Intervention type: DEVICE
Intervention: Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Description: All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
Study: NCT04980833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
Study: NCT06536361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Learning Tool
Description: The intervention involves the use of a virtual reality-based learning tool to teach thorax and lung physical examination skills. The tool uses Oculus Meta Quest 3 VR headset to provide immersive simulation experiences. The VR tool includes high-quality graphics and interactive scenarios to facilitate skill development.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Small Group Training
Description: The intervention involves traditional small group training conducted in the Nursing Principles Skills Laboratory. This training includes hands-on practice with physical examination techniques using simulation mannequins and feedback from instructors. The approach is designed to provide practical experience without the use of virtual reality technology.
Study: NCT06577844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video support
Description: video support provided to the patient before surgery
Study: NCT06578429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active
Description: The study will utilize the H4 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the bilateral insula, a core salience network node.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham
Description: The study will utilize an identical protocol using the H4 coil to administer a sham condition.
Study: NCT05668208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)
Description: ONSD measurement will be made using the E-CUBE i7 ultrasound system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)
Description: ONSD measurement will be made using the E-CUBE i7 ultrasound system.
Study: NCT06102941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CT)
Description: 4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
Study: NCT06345027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment Arm A
Description: Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older.
Study: NCT05879289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A power supplement
Description: A dietary supplement containing vitamins and collagen
Study: NCT05695612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novaloc Attachment
Description: Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locator Attachment
Description: Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
Study: NCT03993054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral stress management
Description: The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-tailored cognitive behavioral stress management
Description: This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
Study: NCT05463796

Intervention type: OTHER
Intervention: Samples
Description: Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Intervention type: OTHER
Intervention: Samples
Description: Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Intervention type: OTHER
Intervention: Samples
Description: Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Intervention type: OTHER
Intervention: Samples
Description: Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues
Study: NCT05966077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT OF SENDING AN SMS
Description: Each subject of the experimental group will receive, in addition to the usual procedure of the VigilanS Lorraine device, an SMS 48 hours before the telephone call for evaluation at 3 months, warning him of this call.~The time of this SMS has been set at 1:00 p.m. for all the people included in this group.~At the end of this evaluation call, the caller will pass a satisfaction questionnaire to the subject in relation to the sending of the SMS
Study: NCT05037201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
Study: NCT05408299

Intervention type: BIOLOGICAL
Intervention: Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
Description: Vaccination

Intervention type: BIOLOGICAL
Intervention: Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
Description: Vaccination
Study: NCT05709678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Sport nutrition education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Education
Description: Sport nutrition education with peer testimonials on negative effects of REDs
Study: NCT06118931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early (7:00 - 16:00) TRE
Description: A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid (9:30 - 18:30) TRE
Description: A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late (12:00 - 21:00) TRE
Description: A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
Study: NCT04693208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
Study: NCT05884736

Intervention type: OTHER
Intervention: Neuromonitoring
Description: Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
Study: NCT06577974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined contraceptive pills (Yasmin)
Description: medical pretreatment prior to ICSI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined contraceptive pills (Yasmin)
Description: medical pretreatment prior to ICSI
Study: NCT06577246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling root planing
Description: periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling root planing
Description: periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Animation (video1-2)
Description: The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-Dimensional Animation (video1-2)
Description: The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-Dimensional Animation (video 3)
Description: iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodontal Disease Prediction (PDP)
Description: The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years. These projections were presented to the patients in three dimensions with PDP visualisation.
Study: NCT06577831

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dynamic MRI
Description: * MRI sequences will be performed for patients and healthy volunteers i~* Vaginal and rectal tagging will be performed using a water-based ultrasound gel.~* The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe.~* MRI sequences.~* Data analysis and interpretation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dynamic MRI
Description: * MRI sequences will be performed for patients and healthy volunteers i~* Vaginal and rectal tagging will be performed using a water-based ultrasound gel.~* The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe.~* MRI sequences.~* Data analysis and interpretation.
Study: NCT06159842

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid 20% Topical Solution with Blue Light
Description: Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
Study: NCT06431932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a corresponding number of placebo capsules for two consecutive days.
Study: NCT04987320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Subcutaneous injection
Study: NCT06087809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and feedback
Description: Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email.
Study: NCT05616650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
Study: NCT05710653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Description: The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
Study: NCT05616650

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
Study: NCT06632457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Subcutaneous injection
Study: NCT05710653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Description: The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Description: The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
Study: NCT04955405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The seven visit telemedicine protocol
Description: The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
Study: NCT05270577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: prehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: No intervention
Study: NCT06632457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching survodutide
Description: Subcutaneous injection
Study: NCT06087809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration.
Study: NCT00622141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic GPO saquinavir and novir vs invirase and norvir
Description: Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
Study: NCT04826081

Intervention type: OTHER
Intervention: data collection
Description: data collection

Intervention type: OTHER
Intervention: data collection
Description: data collection
Study: NCT06578572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21Matrix M
Description: A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
Study: NCT06578260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups with a solution-focused approach
Description: To investigate the effectiveness of a support group intervention using a solution-focused approach among school children in 5th-7th grade in southeastern Norway
Study: NCT04787913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: herdimm
Description: In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.